Dmello et al. (2022) found that the endoplasmic reticulum protein SSR3 (signal sequence receptor subunit 3) was associated with paclitaxel resistance in breast cancer, and that knockdown of SSR3 made cells resistant to PTX, while overexpression made them sensitive to PTX. The gene discussed is SSR3; the disease is breast cancer.